Peer-reviewed veterinary case report
Safety and immune response of new rabies vaccine in dogs
By Yuan, Ziguo et al.·Published in Vaccine·2008·Veterinary Institute, China·View original on PubMed →
PetCaseFinder translated the abstract of this peer-reviewed paper into plain English so pet owners can read it. We do not publish original research — every detail traces back to the citation above. How we work →
Original publication title: A recombinant pseudorabies virus expressing rabies virus glycoprotein: safety and immunogenicity in dogs.
- Species:
- dog
Plain-English summary
A group of dogs received a new oral vaccine designed to protect against rabies, using a modified virus that is safe for them. After just one dose, the dogs developed strong immune responses, showing high levels of antibodies against both rabies and the modified virus. These antibody levels remained elevated for over six months, indicating that the vaccine was effective. This promising approach could improve rabies vaccination strategies for dogs, especially in areas where traditional methods are challenging.
People also search for: dog rabies vaccine effectiveness · oral rabies vaccine for dogs · dog vaccination immune response
Abstract
Several recombinant vaccines expressing the rabies virus glycoprotein have been developed, particularly for the oral vaccination of wildlife. While these vaccines induce protective immunity in some animal species such as foxes, they are less effective in others. Pseudorabies virus (PRV) has been licensed for use as a live vaccine in pigs and possesses an excellent safety and efficacy record. We have used it to construct a recombinant virus, rPRV/eGFP/rgp, expressing the rabies virus glycoprotein. This recombinant virus has been shown to be safe for dogs by oral and intramuscular routes of inoculation and was demonstrated to induce immune responses against both pseudorabies and rabies in dogs after a single oral dose of 2 x 10(7.0) plaque forming units (PFU). Neutralizing antibody titers against rabies reached > 0.5 IU/ml and 1:64-1:128 against pseudorabies by 5 weeks post-vaccination in all dogs, indicating that the pseudorabies virus vector infected dogs and replicated in vivo, and that the rabies virus glycoprotein had been expressed and an effective immune response elicited. Antibody titers were maintained for over 6 months. This suggests that pseudorabies virus could be an effective live vector for recombinant rabies oral vaccination.
Find similar cases for your pet
PetCaseFinder finds other peer-reviewed reports of pets with the same symptoms, plus a plain-English summary of what was tried across them.
Search related cases →Original publication on PubMed: https://pubmed.ncbi.nlm.nih.gov/18262313/